Clinical Trial Detail

NCT ID NCT01647828
Title A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors OncoMed Pharmaceuticals, Inc.
Indications

pancreatic ductal adenocarcinoma

Therapies

nab-paclitaxel

Gemcitabine

Tarextumab

Age Groups: senior adult

No variant requirements are available.